INCY - Incyte Mirati team up for trial of combo therapy for solid tumors
- Incyte ( NASDAQ: INCY ) and Mirati Therapeutics ( NASDAQ: MRTX ) entered a clinical trial collaboration and supply agreement.
- The companies will evaluate a combination of Incyte's small molecule PD-L1 inhibitor INCB99280 and Mirati's KRAS G12C selective inhibitor adagrasib.
- Incyte will start and sponsor a phase 1/1b study of INCB99280 and adagrasib in patients with KRASG12C-mutated solid tumors, the companies noted.
- "Incyte's small molecule, oral PD-L1 program has shown promising safety and efficacy in early studies – INCB99280’s shorter half life may result in improved management of immune mediated adverse events and better clinical outcomes," said Lance Leopold, group vice president, Clinical Development Hematology and Oncology, Incyte.
For further details see:
Incyte, Mirati team up for trial of combo therapy for solid tumors